Northwestern Study Backs ApoB Test Over LDL for 250,000 U.S. Adults
Updated
Updated · ScienceDaily · Jul 6
Northwestern Study Backs ApoB Test Over LDL for 250,000 U.S. Adults
1 articles · Updated · ScienceDaily · Jul 6
Summary
A JAMA study found apoB-guided cholesterol treatment would prevent more heart attacks and strokes than standard LDL or non-HDL testing while remaining cost-effective for U.S. healthcare payers.
The Northwestern team modeled 250,000 U.S. adults eligible for statins but without cardiovascular disease, comparing LDL targets below 100 mg/dL, non-HDL below 118 mg/dL and apoB below 78.7 mg/dL.
ApoB outperformed the other strategies because it counts the total number of harmful cholesterol-carrying particles, which researchers said more directly reflects plaque-building cardiovascular risk than standard cholesterol measures.
The findings arrive as updated U.S. guidelines from the American Heart Association and 10 other groups push cholesterol-lowering therapy to younger ages, raising the stakes for choosing the right test.
Is counting cholesterol 'particles' instead of 'levels' the key to preventing heart disease?
If a better heart attack predictor exists, why isn't it the standard medical test yet?
ApoB Blood Test Surpasses LDL Cholesterol: The 2026 Breakthrough Transforming Heart Disease Risk Assessment
Overview
A major Northwestern Medicine study published in April 2026 highlights the critical role of the apolipoprotein B (apoB) blood test in heart disease risk assessment. Unlike standard cholesterol tests that measure the amount of cholesterol within lipoproteins, apoB directly counts the total number of harmful particles in the blood. This direct measurement provides a more accurate picture of atherogenic burden, making apoB superior at identifying individuals at risk for cardiovascular events. The study’s findings are timely and urge a shift in medical practice, emphasizing the need for more precise and effective cholesterol management.